Zhongsheng Pharmaceuticals: A subsidiary signed a licensing agreement and may receive a payment of 1 billion RMB.

Zongsheng Pharmaceuticals announced that on January 16, 2026, its holding subsidiary Zongsheng Ruichuang signed a "License Agreement" with Qilu Pharmaceutical, authorizing Qilu Pharmaceutical to produce and commercialize RAY1225 injection in the licensed area. Zongsheng Ruichuang retains relevant intellectual property rights, and will be the drug marketing authorization holder after the product is approved, still retaining all overseas rights. Zongsheng Ruichuang will receive a total of 1 billion yuan in upfront payment and milestone payments, including 200 million yuan upfront payment, up to 800 million yuan in development and sales milestone payments, and double-digit sales royalties in the future. This transaction has been approved by the board of directors and does not constitute a related party transaction or a significant asset restructuring.